NCT01761981

Brief Summary

The purpose of this study is to create an institutional and population-based registry of Haemorrhagic Hereditary Telangiectasia with a prospective survey based on epidemiological data, risk factors, diagnosis, prognosis, treatment, monitoring and survival. This study will also describe the occurrence of Haemorrhagic Hereditary Telangiectasia in the population of HIBA in the Central Hospital, as well as the characteristics of clinical presentation and evolution.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
590

participants targeted

Target at P75+ for all trials

Timeline
117mo left

Started Jan 2010

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress63%
Jan 2010Dec 2035

Study Start

First participant enrolled

January 1, 2010

Completed
3 years until next milestone

First Submitted

Initial submission to the registry

January 3, 2013

Completed
4 days until next milestone

First Posted

Study publicly available on registry

January 7, 2013

Completed
12.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 19, 2025

Completed
10.5 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2035

Expected
Last Updated

May 22, 2025

Status Verified

May 1, 2025

Enrollment Period

15.4 years

First QC Date

January 3, 2013

Last Update Submit

May 19, 2025

Conditions

Keywords

Haemorrhagic Hereditary TelangiectasiaRendu Osler Weber SyndromeOsler Weber Rendu SyndromeHHT

Outcome Measures

Primary Outcomes (1)

  • morbidity

    Control visit every three month

    1 year

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients with Haemorrhagic Hereditary Telangiectasia

You may qualify if:

  • Patients with HHT defined.
  • Followed in Unidad HHT of Hospital Italiano de Buenos Aires.

You may not qualify if:

  • \. Denied to participated in the registry or inform consent process.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital Italiano de Buenos Aires

Buenos Aires, Buenos Aires, 1081, Argentina

RECRUITING

Related Publications (1)

  • Serra MM, Besada CH, Cabana Cal A, Saenz A, Stefani CV, Bauso D, Golimstok AB, Bandi JC, Giunta DH, Elizondo CM. Central nervous system manganese induced lesions and clinical consequences in patients with hereditary hemorrhagic telangiectasia. Orphanet J Rare Dis. 2017 May 18;12(1):92. doi: 10.1186/s13023-017-0632-2.

MeSH Terms

Conditions

Telangiectasia, Hereditary Hemorrhagic

Condition Hierarchy (Ancestors)

Hemostatic DisordersVascular DiseasesCardiovascular DiseasesTelangiectasisHemorrhagic DisordersHematologic DiseasesHemic and Lymphatic DiseasesVascular MalformationsCardiovascular AbnormalitiesCongenital AbnormalitiesCongenital, Hereditary, and Neonatal Diseases and Abnormalities

Study Officials

  • Marcelo M Serra, MD

    HHT Center of Excelence Hospital Italiano de Buenos Aires

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Marcelo Martin Serra

Study Record Dates

First Submitted

January 3, 2013

First Posted

January 7, 2013

Study Start

January 1, 2010

Primary Completion

May 19, 2025

Study Completion (Estimated)

December 1, 2035

Last Updated

May 22, 2025

Record last verified: 2025-05

Data Sharing

IPD Sharing
Will not share

Locations